English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The non-invasive prenataldiagnosis of the fetus RhD genotype in RhD incompatibility has a crucial rolein the prevention of increased anti-D immunoglobulin therapy for haemolyticdiseases in pregnant women carrying RhD negative fetus. It was aimed to detectfetal RhD genotyping by using maternal circulating cell-free DNA in the currentstudy.Methods: Maternal blood samples werecollected in different trimester of pregnancies (12-40 weeks) in 12 D-negativemothers. Cell-free fetal DNA was extracted from 2 ml of maternal plasma by anconventional DNA isolation technique (Qiagen, Hilden, Germany) and real-timePCR was performed for genotyping target RhD exons 7 and 10 and GLO genes.Postnatal serological evaluations were performed and the results wereconfirmed.Results: 6 cases (50 %)were determined D positive and 6 cases (50 %) were determined D negative. Allresults were also confirmed after birth serologically.Conclusions: In conclusion,the current results showed us the non-invasive target RhD genotyping from cellfree fetal DNA from maternal plasma samples have a diagnostic accuracy in RhDincompatibility pregnancies.

Maternal plazmadaki hücre dışı serbest fetal DNA kullanılarak girişimsel olmayan fetal RhD genotiplemesinin tanısal doğruluğu